Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA: ALZHEIMER DISEASE~* The participant is 50 years or older.~* Written informed consent is obtained.~* Participants have a clinical diagnosis of Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.~* Mini-Mental Status Exam score \< 25.~* Modified Hachinski Ischemia Scale score of ≤ 4.~* Geriatric Depression Scales (GDS) ≤ 10.~* For females, non-child bearing potential or negative urine or blood pregnancy test on day of 123-I AV151 injection.~EXCLUSION CRITERIA: ALZHEIMER DISEASE~* The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia, or history of significant cerebrovascular disease.~* The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness~* The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).~* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.~* Pregnancy~Concomitant therapy Patients may remain on a stable dose of anticholinesterase medication during the study. Use of donepezil (Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®), tacrine (Cognex®), and memantine (Namenda®) are permitted during the study. Doses of these compounds must be stable for 2 months prior to the study. At each visit after the screening visit, the investigator will ask the patient whether any medications including OTC medications, were taken since the previous visit.~Use of antipsychotics for agitation and benzodiazepines for insomnia or anxiety is permitted. However, the use of these agents is not permitted within the 8 hours prior to administration of cognitive testing.~INCLUSION CRITERIA: HEALTHY VOLUNTEERS~* The participant is 50 years or older.~* Written informed consent is obtained.~* Negative history of neurological or psychiatric illness based on evaluation by a research physician.~* Mini-Mental Status Exam score ≥28.~* For females, non-child bearing potential or negative urine or blood pregnancy test on day of 123-I AV151 injection.~EXCLUSION CRITERIA: HEALTHY VOLUNEERS~* The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness.~* The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery).~* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.~* Pregnancy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Asses [123I] AV151 and SPECT imaging (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues